Radiolabeling of monoclonal anti-CD105 with 177Lu for potential use in radioimmunotherapy
Radiolabeling of monoclonal anti-CD105 with 177Lu for potential use in radioimmunotherapy
复制标题
DOI:
10.1016/j.apradiso.2009.02.071
复制
发表时间:
2009-07-01
影响因子:
1.6
通讯作者:
Choi, Sun-Ju
中科院分区:
文献类型:
--
作者:
Lee, So-Young;Hong, Young-Don;Choi, Sun-Ju
In this study, we carried out a radioimmunoconjugation using Lu-177 with anti-CD105 (endoglin) monoclonal antibody for an angiogenesis targeting. CD105 has been shown to be a more useful marker to identify proliferating endothelium involved in tumor angiogenesis than panendothelial markers. We optimized the labeling of the anti-CD105 monoclonal antibody with Lu-177 by using cysteine derivative isothiocyanatobenzyl-DTPA (DTPA-NCS) as BFCA. Under the optimal conditions, labeling yield was greater than 99%. Immunoactivity of the radioimmunoconjugate was investigated using combinations of radioanalytical and bioanalytical techniques (ITLC-SG, Cyclone phosphorimager, SDS-PAGE and ELISA). For the biological evaluations we carried out a cell binding assay and a biodistribution study using mice bearing Calu6 lung cancer cell xenografts. The tumor-to-blood ratio was 11.16:1 24h post-injection. In conclusion, the anti-CD105 monoclonal antibody for an angiogenesis targeting was effectively radioconjugated with Lu-177. And the biodistribution study showed a high specificity for accumulating in tumor tissues. This radjoimmunoconjugate is applicable to detect angiogenesis sites in various diseases and to treat tumors. (C) 2009 Elsevier Ltd. All rights reserved.